CN114848730B - 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 - Google Patents
一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 Download PDFInfo
- Publication number
- CN114848730B CN114848730B CN202210639905.8A CN202210639905A CN114848730B CN 114848730 B CN114848730 B CN 114848730B CN 202210639905 A CN202210639905 A CN 202210639905A CN 114848730 B CN114848730 B CN 114848730B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- traditional chinese
- plasma cell
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 150000001875 compounds Chemical class 0.000 title claims abstract description 53
- 206010066170 Plasma cell mastitis Diseases 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000001154 acute effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 30
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 13
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 13
- 208000002193 Pain Diseases 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims description 22
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 20
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 20
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 20
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 240000007164 Salvia officinalis Species 0.000 claims description 12
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 235000005412 red sage Nutrition 0.000 claims description 12
- 230000001363 autoimmune Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 241001061264 Astragalus Species 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 241000576429 Forsythia suspensa Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 210000004233 talus Anatomy 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 240000006688 Telosma cordata Species 0.000 claims description 2
- 235000017352 Telosma cordata Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 10
- 206010016717 Fistula Diseases 0.000 abstract description 6
- 230000003890 fistula Effects 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 208000004396 mastitis Diseases 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 206010006262 Breast inflammation Diseases 0.000 abstract 1
- 206010006298 Breast pain Diseases 0.000 abstract 1
- 208000006662 Mastodynia Diseases 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000022766 lymph node neoplasm Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 230000008961 swelling Effects 0.000 description 11
- 241000245665 Taraxacum Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229910001220 stainless steel Inorganic materials 0.000 description 10
- 239000010935 stainless steel Substances 0.000 description 10
- 229940107666 astragalus root Drugs 0.000 description 9
- 244000137773 Viola philippica Species 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 208000033809 Suppuration Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004883 areola Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CNLSPQQMAJCIFB-UHFFFAOYSA-N benzoic acid;ethanol Chemical compound CCO.OC(=O)C1=CC=CC=C1 CNLSPQQMAJCIFB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- -1 decoction Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明提供一种治疗急性浆细胞乳腺炎的复方中药组合物及其制备方法和用途,属于中医药技术领域。本发明的复方中药组合物由下述重量份配比的中药原料组成:金银花5‑15份,漏芦5‑15份,蒲公英10‑20份,连翘10‑20份,黄芪15‑25份,丹参5‑15份,炙甘草5‑15份,紫花地丁15‑25份组成。经体内外试验和临床试验表明,本发明提供的复方中药组合物,配比科学合理,具有清热解毒、散结消肿、消炎止痛等功效,可以调控关键炎症免疫靶点,增强机体免疫,消除乳房红肿疼痛、消除淋巴结肿块并愈合瘘管创面,治疗急性浆细胞乳腺炎的作用。
Description
技术领域
本发明属于中医药技术领域,具体涉及一种治疗急性浆细胞乳腺炎的复方中药组合物制剂。
背景技术
浆细胞乳腺炎(Plasm cell mastitis, PCM)又称乳腺导管扩张症,是一种常发于非哺乳期,以导管扩张和浆细胞浸润为病变基础的乳腺炎症,以临床进展表现分为急性浆细胞乳腺炎以及慢性浆细胞乳腺炎。其中,急性浆细胞乳腺炎可出现同侧腋窝淋巴结肿大且压痛,乳晕周围肿块伴有疼痛,皮肤红肿等急性炎症表现,部分患者可继发感染形成乳腺脓肿。目前临床上治疗浆细胞乳腺炎的方法主要是手术、激素治疗或引流治疗。手术或引流的方法存在切口延迟愈合、术后乳房外形改变对患者心理造成一定的负担等问题;激素治疗存在较大副作用的问题。浆细胞乳腺炎的病因尚不明确,有相关研究表明,浆细胞乳腺炎与自身免疫系统紊乱或自身免疫系统缺陷密切相关。我们在研究中也发现浆细胞乳腺炎的发生发展与炎症免疫系统的失调密切相关,并建立了浆细胞乳腺炎分子靶标的医学医药知识图谱,以促进浆细胞乳腺炎治疗方法及治疗药物的开发。综上,浆细胞性乳腺炎属于乳腺疾病中缺乏临床有效治疗手段的复杂性疾病。
JAK2/STAT3是人体炎症以及自身免疫系统相关通路,磷酸化的JAK2和STAT3蛋白都是该通路被激活的重要标记,被激活后JAK2/STAT3以二聚体的形式进入细胞核调节目的基因表达。该信号通路的异常与自身免疫系统疾病的发生发展息息相关, 与人体免疫系统功能密切相关。目前,已有相关研究表明,JAK2/STAT3通路的异常激活与浆细胞乳腺炎、炎症性肠病、银屑病等自身免疫系统疾病的病理进程密切相关。
中医药在治疗复杂性疾病方面具有独特的优势,以中药为代表的天然药物具有毒副作用小、耐受性好等特点。中医药理论强调辩证施治,一方面补人体之虚,对患者的免疫功能进行调控;另一方面解毒散结以治疗疾病,注重治病与调理的统一,改善全身状态。目前,中医理论认为浆细胞乳腺炎的发生与肝郁胃热相关, 即肝经郁热是该病症的主要发病机制。我们在急性浆细胞乳腺炎的研究中并结合临床实践发现了一种复方中药组方制剂,用药量小且配比科学合理,可有效的治疗急性浆细胞乳腺炎。此外,该组方制剂可以调控异常激活的JAK2/STAT3信号通路,下调磷酸化的JAK2和STAT3蛋白,进而调节浆细胞乳腺炎患者自身免疫系统及整体免疫功能,消炎去肿并愈合瘘管,有望给急性浆细胞乳腺炎的临床治疗提供一种低毒高效的治疗方法。
发明内容
针对上述问题,本发明提供一种治疗急性浆细胞乳腺炎的复方中药组合物,本发明的另一个目的是提供该复方中药组合物的制备方法及其在制备治疗急性浆细胞乳腺炎药物中的应用。
为了实现上述目的,本发明提供了如下技术方案。
本发明提供了一种治疗急性浆细胞乳腺炎的复方中药组合物,其特征在于,所述的中药组合物包含下述重量份配比的中药原料的提取物组成:金银花5-15份,漏芦5-15份,蒲公英10-20份,连翘10-20份,黄芪15-25份,丹参5-15份,炙甘草5-15份,紫花地丁15-25份。
进一步地,所述各原料药的重量份数配比是:金银花10份,漏芦8份,蒲公英15份,连翘15份,黄芪20份,丹参10份,炙甘草8份,紫花地丁20份。
进一步地,如上所述组合物还包含药学上可接受的载体和/或赋形剂。
优选地,所述药学上可接受的载体和/或赋形剂选自脂质体、微晶纤维素、羧甲基淀粉钠、羧甲基纤维素钠、聚乙二醇、聚乙烯醇、丙烯酸酯类聚合物、甘油、丙二醇、山梨醇、β-环糊精、吐温-80、乳糖、淀粉、尤奇特S-100、尤奇特L-100、海藻酸钠、果胶、糊精中的一种或多种。
进一步地,如上所述组合物的剂型为颗粒剂、胶囊剂、口服液、片剂、丸剂、膏剂、汤剂、注射剂和微囊剂。
一种根据上述中任一项所述的一种治疗急性浆细胞乳腺炎的复方中药组合物的制备方法,选自:
A:处方中药加水5-12倍量共煎煮,滤过,滤液浓缩;
B:处方中药加50-90%浓度的乙醇水溶液回流提取,滤过,滤液浓缩;
C:处方中药加水5-12倍量共煎煮,滤过;药渣加50-90%浓度乙醇水溶液回流提取,滤过,滤液合并浓缩。
进一步地,所述的乙醇水溶液回流提取操作中乙醇水溶液用量为药材重量8-10倍。
进一步地,如上所述的复方中药组合物在制备用于治疗急性浆细胞乳腺炎的药物中的应用。
本发明所提供的调节肿瘤免疫并抗肿瘤的复方中药组合物的原料药功效如下。
金银花性寒味甘,归心、肺、胃经,具有清热解毒、凉散风热、抗氧化、调节免疫的功效。
漏芦性寒味苦,归胃经,具有清热解毒、排脓通乳的功效。
蒲公英性寒微苦,归肝、胃经,具有清热解毒、消肿散结、利尿通淋,增强免疫细胞功能并抗肿瘤的功效。
连翘性寒微苦,归肺经、心经,具有清热解毒、消肿散结、提升免疫并抗病毒的功效。
黄芪性温味甘,归肺、脾经,具有补气升阳、利水消肿、生津养血、托毒排脓、提升免疫功效;。
丹参性寒味苦,归心、肝经,具有祛瘀止痛、活血通经、清心除烦、提升免疫的功效。
炙甘草性温味甘,归心、肺、胃、脾经,具有补脾和胃、益气复脉的功效。
紫花地丁性寒味苦,归心、肝经,具有清热解毒、凉血消肿的功效。
以上诸药合用以中医的“君臣佐使”理论为依据,合理配置,相互配伍。本发明中以金银花、蒲公英、连翘、紫花地丁清热解毒、凉血消肿为君药;丹参、漏芦活血化瘀、散结消肿、排脓通乳为臣药;黄芪补气消肿、托毒排脓、提升免疫为佐药;炙甘草清热解毒,调和诸药为使药。八药合而为用,共奏诸药合用共奏清热解毒、活血止痛、提升免疫之功效。
与现有技术相比本发明的有益效果。
1. 本发明根据中医药理论,同时结合浆细胞乳腺炎的最前沿研究结果,采用辩证论治全身调节的原则进行中药组方筛选,提供的复方中药组合制剂可以调控炎症免疫关键通路靶点,对急性浆细胞乳腺炎具有很好的治疗效果。
2. 实验结果表明本发明提供的治疗急性浆细胞乳腺炎的复方中药组合物,具有清热解毒和活血止痛的作用,同时可以调控异常的JAK2/STAT3信号通路,下调磷酸化的JAK2和STAT3蛋白,进而调节浆细胞乳腺炎患者自身免疫系统及整体免疫功能,发挥多靶点系统治疗急性浆细胞乳腺炎的作用,并减少急性浆乳患者痛苦。临床实践表明,本发明提供的治疗急性浆细胞乳腺炎的复方中药组合物安全性很高,毒副作用很低。
3. 本发明提供的治疗急性浆细胞乳腺炎的复方中药组合物可以利用药学载体/赋形剂等制备成多种剂型,患者服用方便。此外,本发明提供的治疗急性浆细胞乳腺炎的复方中药组合物配比科学合理,用药量少,能较快发挥药效,制备工艺稳定,适合工业化大规模生产。
具体实施方式
下面结合具体实施例对本发明做详细的说明。以下实施例将有助于对本发明的了解,但这些实施例仅为了对本发明加以说明,本发明并不限于这些内容。在实施例中的操作方法均为本技术领域常规操作方法。
实施例1
按重量份数取原料药,取金银花15克,漏芦15克,蒲公英20克,连翘20克,黄芪25克,丹参15克,炙甘草15克,紫花地丁25克。按照复方中药的重量加水12倍即1800mL共煎煮,提取3次,每次2小时,120目不锈钢网自然滤过,浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入稀释剂乳糖以及玉米淀粉混合均匀,装入肠溶胶囊并制备成复方中药的胶囊剂(批号:A001)。
实施例2
按重量份数取原料药,取金银花10克,漏芦10克,蒲公英15克,连翘15克,黄芪20克,丹参10克,炙甘草10克,紫花地丁20克。 按照复方中药的重量加水10倍即1100mL水共煎煮,提取3次,每次2小时,120目不锈钢网自然滤过, 浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入微晶纤维素、羧甲基淀粉钠,并加入润滑剂硬脂酸镁,混合均匀后,压片制备成片剂(批号:A002)。
实施例3
按重量份数取原料药,取金银花5克,漏芦5克,蒲公英10克,连翘10克,黄芪15克,丹参5克,炙甘草5克,紫花地丁15克。按照复方中药的重量加水8倍即560mL水共煎煮,120目不锈钢网自然滤过,药渣加入10倍重量份的50%乙醇700mL回流提取,120目不锈钢网自然滤过,将过滤液合并,浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入甘油及山梨醇等赋形剂制备成内服的复方中药膏剂(批号:A003)。
实施例4
按重量份数取原料药,取金银花10克,漏芦8克,蒲公英15克,连翘15克,黄芪20克,丹参10克,炙甘草8克,紫花地丁20克。按照复方中药的重量加8倍70%的乙醇溶液即848mL乙醇溶液回流提取,提取3次,每次2小时,120目不锈钢网自然滤过, 浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入丙烯酸酯类聚合物、聚乙二醇等赋形剂及粘结剂,采用融溶法制备成复方中药的滴丸剂型(批号:A004)。
实施例5
按重量份数取原料药,取金银花10克,漏芦8克,蒲公英15克,连翘15克,黄芪20克,丹参10克,炙甘草8克,紫花地丁20克。按照复方中药的重量加10倍的90%的乙醇溶液即1060mL乙醇溶液回流提取,提取3次,每次2小时,120目不锈钢网自然滤过,浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入海藻酸钠、低聚木糖及果胶,经微囊化包埋,并利用喷雾干燥技术处理,制备成复方中药的微囊剂(批号:A005)。
实施例6
按重量份数取原料药,取金银花10克,漏芦8克,蒲公英15克,连翘15克,黄芪20克,丹参10克,炙甘草8克,紫花地丁20克。按照复方中药的重量加水10倍即1060mL水共煎煮,120目不锈钢网自然滤过,药渣加入8倍重量份的50%乙醇848mL回流提取,120目不锈钢网自然滤过,将过滤液合并,浓缩物上大孔吸附树脂柱,洗脱后得到浓缩液。将浓缩液置于配液罐中,向中药浓缩液中缓慢加入苯甲酸乙醇溶液和山梨酸乙醇溶液,同时加入调味剂,制备得到复方中药的口服液(批号:A006)。
实施例7
按重量份数取原料药,取金银花10克,漏芦8克,蒲公英15克,连翘15克,黄芪20克,丹参10克,炙甘草8克,紫花地丁20克。按照复方中药的重量加水10倍即1060mL水共煎煮,120目不锈钢网自然滤过,药渣加入10倍重量份的70%乙醇1060mL回流提取,提取3次,每次2小时,120目不锈钢网自然滤过,将过滤液合并,浓缩物上大孔吸附树脂柱,洗脱后进一步减压浓缩成测定相对密度为1.20-1.30的浸膏,真空干燥后,低温超微粉碎得细粉,加入糊精,喷雾制得复方中药的颗粒剂(批号:A007)。
实施例8
通过脂多糖(LPS)刺激诱导的乳腺炎细胞模型来评估本发明实施例制备得到的复方中药组合物制剂对JAK2/STAT3信号通路及人体免疫系统功能的调控作用。JAK2/STAT3是人体自身免疫系统相关通路,该信号通路的异常与自身免疫系统疾病的发生发展息息相关, 与人体免疫系统功能密切相关。体外培养小鼠巨噬细胞Raw264.7,利用1μg/mL浓度的脂多糖作用于小鼠巨噬细胞Raw264.7刺激诱导建立体外乳腺炎细胞模型。将诱导后的细胞用胰酶进行消化、计数、制成浓度为6×104个/mL的细胞悬液。将96孔板中每孔加入100μL细胞悬液(每孔6×103个细胞),然后置于培养箱中培养24小时。将上述实施例1-7中的组方中药制剂配制成50mg/mL的水溶液;AG-490是一种经典的JAK2/STAT3通路的小分子抑制剂,用DMSO将AG-490配制成50mg/mL的溶液,混合均匀后将这些药物溶液加入2μL到96孔白色酶标板中。JAK2抗体以及磷酸化JAK2抗体(p-JAK2),STAT3抗体以及磷酸化STAT3抗体(p-STAT3)均购自Abcam公司。利用Western技术并结合ImageJ等软件定量计算确定药物处理细胞后p-JAK2/JAK2的含量比例以及p-STAT3/STAT3的含量比例。处理后如果这两个比例降低,则说明药物有效地下调了JAK2/STAT3信号通路及相关靶点,进而对自身免疫系统以及免疫功能起到调控作用。组别分成缓冲液(9%的Saline溶液)、AG-490对照药物组、以及七组本发明实施例制备得到的中药组合物制剂的处理组。
表1. 中药组合物制剂对JAK2/STAT3信号通路及免疫系统功能的调控作用评估
。
本实验表明,批号A004-007的复方组合物制剂对JAK2/STAT3信号通路的调控作用要强于批号A001-003的复方组合物制剂,证明批号A004-007的组方配比较优。此外,批号A004-007的复方组合物制剂对JAK2/STAT3信号通路的调控作用与对照药物AG-490的调控作用相当,证明复方中药组合物制剂对免疫系统功能以及整体免疫有较好的调控作用。
实施例9
通过临床试验研究来评估本发明的复方中药组方产品的治疗急性浆细胞乳腺炎作用。采用开放、随机对照设计,共纳入50例急性浆细胞乳腺炎患者。受试者年龄在20-60岁,入选标准符合急性浆细胞乳腺炎患者的女性患者,诊断标准如下:
1. 乳腺B超、钼靶、MRI在组织病理学上诊断为急性浆细胞乳腺炎;
2. 发病以一侧或双侧乳晕周围有肿块并伴有疼痛、皮肤红肿、成脓等急性浆细胞乳腺炎的病理表现;
3. 溃后形成脓液且不收口、形成乳漏。经病理组织学证实为急性浆细胞乳腺炎患者。
凡有以下情况之一,则不能参加临床试验研究:
1. 入组前1个月使用过激素及免疫抑制治疗;
2. 有严重基础疾病患者、例如糖尿病、心血管疾病、造血系统疾病等;
3. 怀孕期或者哺乳期女性患者;
4. 对中药不耐受或者依从性差;
5. 近期服用过抗抑郁药和其他精神类药物者。
入组患者每日口服服用复方中药组方产品(实施例产品批号:A007),每次10g/袋,每天两次。每3周为1周期,总计6周期。每个周期复查彩超评价治疗疗效,临床观察评估复方中药组方产品的治疗效果;每2个周期采集外周血检测炎症免疫指标,利用流式细胞术及ELISA试剂盒检测炎症免疫细胞因子包括IL-1β,TNF-α等在治疗前后的含量变化,用来评估复方中药组方产品的治疗效果。
临床观察及疗效标准
根据浆细胞乳腺炎的中医辨证标准以及《中药新药临床指导原则》制定浆细胞乳腺炎的病理症状,并依据病理体征将疗效划分为痊愈、基本痊愈、显效、有效、无效五个等级:A.痊愈:乳房红肿疼痛完全消失、淋巴结肿块消失、瘘管愈合,乳腺B超、钼靶、MRI等技术在组织病理学上诊断为痊愈;B.基本痊愈:乳房红肿疼痛基本消失、淋巴结肿块基本消失、瘘管基本愈合;C.显效:乳房红肿疼痛显著减轻、有淋巴结肿块、有潜在创口未愈、瘘管大部分愈合;D.有效:乳房红肿疼痛有减轻、有淋巴结肿块, 瘘管、创面等开始愈合;E.无效:没有治疗效果或病变范围扩大。
表2. 临床观察复方中药组方产品治疗前后的疗效评价结果
。
结果表明,复方中药组方产品治疗后,急性浆细胞乳腺炎患者患者达到痊愈或基本痊愈的比例达到78%,达到有效或显效的比例达到20%。
表3. 治疗周期后采集患者外周血检测炎症免疫指标的结果
。
结果表明,复方中药组方产品治疗后,急性浆细胞乳腺炎患者患者的炎症细胞因子的含量显著下降,表示复方中药组方产品有效地调控了患者的炎症免疫通路,治疗效果良好。
Claims (6)
1.一种治疗急性浆细胞乳腺炎的复方中药组合物,其特征在于,所述中药组合物由下述重量份配比的中药原料制成:金银花10份,漏芦8份,蒲公英15份,连翘15份,黄芪20份,丹参10份,炙甘草8份,紫花地丁20份,所述复方中药组合物的制备方法,选自:A:处方中药加水5-12倍量共煎煮,滤过,滤液浓缩;B:处方中药加50-90%浓度的乙醇水溶液回流提取,滤过,滤液浓缩,所述乙醇水溶液回流提取操作中乙醇水溶液用量为药材重量8-10倍;C:处方中药加水5-12倍量共煎煮,滤过;药渣加50-90%浓度乙醇水溶液回流提取,滤过,滤液合并浓缩,所述乙醇水溶液回流提取操作中乙醇水溶液用量为药材重量8-10倍,所述复方中药组合物具有清热解毒和活血止痛的作用,同时调控异常的JAK2/STAT3信号通路,下调磷酸化的JAK2和STAT3蛋白,进而调节浆细胞乳腺炎患者自身免疫系统。
2.根据权利要求1所述的一种治疗急性浆细胞乳腺炎的复方中药组合物,其特征在于,所述组合物还包含药学上可接受的载体。
3.根据权利要求2所述的一种治疗急性浆细胞乳腺炎的复方中药组合物,其特征在于,所述药学上可接受的载体选自脂质体、微晶纤维素、羧甲基淀粉钠、羧甲基纤维素钠、聚乙二醇、聚乙烯醇、丙烯酸酯类聚合物、甘油、丙二醇、山梨醇、β-环糊精、吐温-80、乳糖、淀粉、尤奇特S-100、尤奇特L-100、海藻酸钠、果胶、糊精中的一种或多种。
4.根据权利要求1所述的一种治疗急性浆细胞乳腺炎的复方中药组合物,其特征在于,所述组合物的剂型为颗粒剂、胶囊剂、口服液、片剂、丸剂、膏剂或微囊剂。
5.根据权利要求1-4中任一项所述的一种治疗急性浆细胞乳腺炎的复方中药组合物的制备方法,选自:A:处方中药加水5-12倍量共煎煮,滤过,滤液浓缩;B:处方中药加50-90%浓度的乙醇水溶液回流提取,滤过,滤液浓缩,所述乙醇水溶液回流提取操作中乙醇水溶液用量为药材重量8-10倍;C:处方中药加水5-12倍量共煎煮,滤过;药渣加50-90%浓度乙醇水溶液回流提取,滤过,滤液合并浓缩,所述乙醇水溶液回流提取操作中乙醇水溶液用量为药材重量8-10倍。
6.根据权利要求1-4中任一项所述的复方中药组合物在制备用于治疗急性浆细胞乳腺炎的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210639905.8A CN114848730B (zh) | 2022-06-08 | 2022-06-08 | 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210639905.8A CN114848730B (zh) | 2022-06-08 | 2022-06-08 | 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114848730A CN114848730A (zh) | 2022-08-05 |
CN114848730B true CN114848730B (zh) | 2023-11-21 |
Family
ID=82625378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210639905.8A Active CN114848730B (zh) | 2022-06-08 | 2022-06-08 | 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114848730B (zh) |
-
2022
- 2022-06-08 CN CN202210639905.8A patent/CN114848730B/zh active Active
Non-Patent Citations (1)
Title |
---|
郦红英.辨证分期治疗浆细胞性乳腺炎50例.辽宁中医药大学学报.-,2010,第12卷(第12期),152-153. * |
Also Published As
Publication number | Publication date |
---|---|
CN114848730A (zh) | 2022-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102940779B (zh) | 一种治疗慢性溃疡性结肠炎的药物组合物及其制备方法 | |
CN1051237C (zh) | 治疗癫痫病的药物 | |
CN102626468B (zh) | 一种治疗乙肝的中药组合物及其制备方法和应用 | |
CN1966052A (zh) | 丹黄祛瘀片及制备方法 | |
CN103285119A (zh) | 一种治疗自身免疫性肝病的中药组合物及其制备方法 | |
CN106421673A (zh) | 一种治疗hpv病毒感染的中药组合物及其制备方法 | |
CN1709302A (zh) | 治疗慢性盆腔炎的中药制剂及其制备方法 | |
CN102133273B (zh) | 一种中药降脂通便胶囊及其制备方法 | |
CN114848730B (zh) | 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
CN114848710B (zh) | 一种治疗慢性浆细胞乳腺炎的复方中药组合物的制备及应用 | |
CN108355124B (zh) | 一种治疗气道粘液高分泌的中药组合物及其应用 | |
CN102552724B (zh) | 一种治疗高血压的中药组合物 | |
CN1517115A (zh) | 治疗慢性盆腔炎的中成药——妇炎胶囊 | |
CN103083445A (zh) | 治疗皮肤溃疡的中药制剂及其制备方法 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
CN103655771A (zh) | 治疗皮肤溃疡的中药制剂及其制备方法 | |
CN112138105B (zh) | 一种治疗支气管扩张症肺脾气虚、痰湿阻肺证的中药组合物及其应用 | |
CN101698037A (zh) | 一种治疗崩漏的药物及其制备工艺 | |
CN100560087C (zh) | 治疗恶性肿瘤的药物组合物及其制备方法 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN117442698A (zh) | 中药组合物在制备用于外邪疠气的药物中的应用 | |
CN116966227A (zh) | 一种用于治疗骨折的组合物及其制备方法 | |
CN117414398A (zh) | 一种中药组合物及其在治疗脉管炎中的用途 | |
CN104001077A (zh) | 一种治疗尿路感染的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |